| |AUGUST 20269WHY FAKE MEDICINES PERSIST DESPITE INDIA'S DRUG CONTROL PUSHINDIAN SKINCARE ENTERS A NEW HORIZON WITH WIPRO'S DERMATOUCH DEALAMYLYX DRUG CUTS DANGEROUS LOW BLOOD SUGAR EPISODES BY 55 PERCENTMADE IN INDIA HEART-LUNG MACHINE SET TO CHALLENGE IMPORTSEBOLA CASES CROSS 5,000 IN CONGO AS OUTBREAK DEFIES CONTAINMENTFake medicines remain a serious threat to India's pharmaceutical ecosystem, even as regulators continue to tighten drug-control measures and enforcement. A fresh raid near Bidadi in Karnataka has exposed how counterfeit products can move beyond illegal manufacturing into repacking, relabeling and potential hospital supply chains.The Karnataka drug enforcement authorities seized material estimated at Rs 4.91 crore, including thousands of vials, expired medicines, counterfeit labels and packaging equipment. Reports also indicated that some seized products carried names of major pharmaceutical companies. POIndian skincare is entering a new growth phase as established consumer companies move deeper into premium and science-backed beauty. Wipro Consumer Care & Lighting's acquisition of Dermatouch marks a major step in this direction.Wipro will initially acquire a 60 per cent stake in the Ahmedabad-based skincare brand and take the remaining 40 per cent over three years. The deal Amylyx Pharmaceuticals' low blood sugar drug avexitide has delivered strong results in a late-stage trial. The experimental treatment cut hypoglycemic episodes by 55 percent versus placebo. The results came from a 78-patient trial involving people who had undergone weight-loss surgery.The trial met its main goal after 16 weeks. The results also pushed Amylyx shares more than 45 percent higher during Tuesday trading. The stock reached USD 31.72 in morning trading. The jump could add about USD 1.15 billion to the company's market value. POIndia's heart-lung machine market is set for a major shift as a homegrown device gains key regulatory approvals. The heart-lung machine developed by Mediyant Technologies has received USFDA 510(k) clearance and CDSCO approval.The device is called the New Century Heart-Lung Machine. It is designed for use during open-heart surgeries. The machine supports blood circulation and oxygenation when the heart and lungs are temporarily stopped. Mediyant Technologies developed the device after years of work on indigenous cardiac care technology. The company has secured approval to manufacture and market the machine in India. POEbola cases in the Democratic Republic of Congo (DRC) have crossed 5,000, marking a new and alarming phase in the country's fastest-growing Ebola outbreak. Government data showed 5,021 confirmed cases as of August 16, along with 2,378 deaths. Health officials are warning that the response is struggling to keep pace with the rapid spread of the virus.The outbreak, which was declared on May 15, has already surpassed the 2018­2020 Ebola epidemic in both infections and deaths, making it the largest Ebola outbreak in the DRC's history. The current crisis is also the second-deadliest Ebola outbreak recorded globally, behind the 2014­2016 West Africa epidemic. POgives Wipro its first digital-first brand and a direct entry into India's premium skincare segment. The transaction also highlights growing corporate interest in India's fast-expanding dermal and specialized skincare categories. PO
< Page 8 | Page 10 >